Autobio forming a pattern of immunodiagnostic products and microbiological te
Founded in 1999, Antu Biological is specialized in the development, production and sales of in vitro diagnostic reagents and instruments, forming a pattern of immunodiagnostic products and microbiological testing products. The company's products cover a wide range of testing fields from infectious diseases to non-infectious diseases, and can meet the various testing needs of end users. The reagents cover infectious diseases, tumors, reproductive endocrinology, thyroid function, liver fibrosis, eugenics, diabetes, hypertension, heart disease, genitourinary tract diseases, respiratory diseases, bacterial isolation and culture, identification and susceptibility analysis and other testing fields. In addition, the company has always insisted on the joint development of reagents and instruments, and the related equipment covers chemiluminescence immunoassay analyzer, enzyme labeling instrument, plate washer, laboratory analyzer, automatic sample processing system, automatic chemiluminescence analyzer and other products.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery
The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.
Mar 30, 2023 04:00 PM
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
2022 China AI Health 30 Report
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn
YingHe Neuro Raises Over CNY 100 Mn in Angel Round
Medical Equipment Company PowerSite Nets Over CNY 100 Mn in Series B
HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D
Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.
Apr 23, 2023 12:20 PM
Artificial Cardiac Company CoretechMed Raises Nearly CNY 200 Mn in Series C+
In the past five years, China's ventricular assist technology (i.e., "artificial heart") has developed rapidly, and three domestic implantable ventricular assist devices (LVADs) have been approved and marketed by the State Drug Administration, and another one is in the marketing declaration stage. The number of LVAD implantations has increased yearly, with a total of 363 LVAD implantations performed in 70 hospitals, a rapid increase.
Apr 17, 2023 05:12 PM
Anhui Province has purchased more than 1.1 million tons of summer grain, and the quality of wheat is the best in recent 10 years
Pingzhi information: the subsidiary pre won the bid for the 33.3 million yuan Inner Mongolia Mobile procurement project
Zhejiang Longsheng: all subsidiaries in Shangyu District of Hangzhou Bay began to gradually reduce and orderly temporarily stop production
Global Leader in Radiosurgery Robots ZAP Sets Up China Headquarters in Suzhou
The China headquarters project of the ZAP-X photon surgery robot, led by ZAP, a global leader in the next-generation robotic surgical systems and a leading player in non-invasive brain surgery robots, has officially signed an agreement to settle in Suzhou.
Apr 13, 2023 04:06 PM
Clinical Microbiology Testing Company WillingMed Nets More than 100 Mn in Series B
WillingMed has independently developed and successfully reported and approved a series of automated testing instruments, software, testing reagents and other IVD products, and obtained intellectual property rights for more than 40 core technologies.
Apr 07, 2023 09:09 PM
Nippon instruments: the profit in the first three quarters is expected to drop by 58% - 63%
Zhongyuan expressway: the net profit in the first half of the year was 642 million yuan, turning losses into profits year-on-year
Pharmaceutical and medical stocks fell sharply in early trading, and Hengrui pharmaceutical fell more than 9%
Antu biological: no impact on production and operation, emergency measures have been launched